Kevin J. Black, M.D.


Neurosciences Program

  • 314-362-5041

  • 314-362-5041

  • 314-362-0168

  • 8134

  • East Bldg., Rm 2106



  • fMRI, imaging, movement disorders, Tourette syndrome, pharmacology, PET

  • (1) Functional neuroimaging with dopaminergic challenges using PET and fMRI; (2) Tourette syndrome; (3) Neuropsychiatry of movement disorders

Research Abstract:

My clinical interests focus on the interface between psychiatry and movement disorders. Areas of interest include traditionally psychiatric movement disorders (including Huntington`s disease, Tourette syndrome, tardive dyskinesia, catatonia, motor signs in affective and psychotic disorders, and so-called psychogenic movement disorders) as well as psychological symptoms in traditionally neurological movement disorders (e.g. Parkinson`s disease, Sydenham`s chorea, Huntington disease, and dystonia). I am especially interested in the "pre-Tourette" period in children with tics, and in depression in Parkinson disease.

My imaging research is influenced by these clinical interests and is primarily focused on functional imaging of the dopaminergic system. In many diseases (e.g. idiopathic dystonia, schizophrenia, Tourette syndrome) there are a number of reasons to suspect a functional abnormality of dopamine-influenced basal ganglia circuits, yet many studies of specific elements of these pathways have been equivocal or negative. By giving a dopamine agonist, we "push on" these systems in a manner analogous to the clinical glucose challenge test, and we measure the response to the agonist using PET and functional MRI methods. Colleagues and I have applied this to studies of Parkinson`s disease and Tourette syndrome. I developed a new method for single-session quantitative pharmacodynamic fMRI and a statistical method for associating deep brain stimulation location with clinical benefit. Current NIH-funded research includes PET and fMRI studies of Tourette syndrome.

Selected Publications:

Black KJ, Piccirillo ML, Koller JM, Hseih T, Wang L, Mintun M: Levodopa-stimulated dopamine release in Tourette syndrome. (submitted)

Eisenstein S, Koller JM, Black KD, Ushe M, Tabbal SD, Karimi M, Campbell MC, Lugar HM, Hershey T, Perlmutter JS, Black KJ: Three-dimensional statistical mapping of motor and non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson disease. (submitted)

Black KJ, Koller JM, Miller BD: Rapid quantitative pharmacodynamic imaging by a novel method: Theory, simulation testing and proof of principle. PeerJ 2013; 1:e117;

Campbell MC, Black KJ, Weaver PM, Lugar HM, Videen TO, Tabbal SD, Karimi M, Perlmutter JS, Hershey T (2012): Mood response to deep brain stimulation of the subthalamic nucleus in Parkinson disease. Journal of Neuropsychiatry and Clinical Neurosciences,24(1):28-36. PMCID: PMC3354989

Black KJ, Koller JM, Campbell MC, Gusnard DA, Bandak SI (2010). Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. Journal of Neuroscience, 30(48):16284-16292. PMCID: PMC3008651

Gordon MR, Markham J, Hartlein JM, Koller JM, Loftin S, Black KJ (2007). Intravenous levodopa administration in humans based on a two-compartment kinetic model. Journal of Neuroscience Methods, 159:300-307. Full text:

Wang L, Lee DY, Bailey E, Hartlein JM, Gado MH, Miller MI, Black KJ (2007). Validity of large-deformation high dimensional brain mapping of the basal ganglia in adults with Tourette syndrome. Psychiatry Research (Neuroimaging), 154:181-190. PMCID: PMC2859464

Black KJ, Hershey T, Hartlein JM, Carl JL, Perlmutter JS (2005). Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson disease. Neuropsychopharmacology, 30:590-601. Full text:

Hershey T, Black KJ, Hartlein J, Barch DM, Braver TS, Carl JL, Perlmutter JS (2004). Cognitive-pharmacologic fMRI in Tourette syndrome: A pilot study. Biological Psychiatry, 55:916-925. Full text:

Black KJ, Hershey T, Koller JM, Videen TO, Mintun MA, Price JL, Perlmutter JS (2002): A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc Natl Acad Sci U S A, 99(26):17113-17118. PMCID: PMC139278

Last Updated: 7/30/2013 10:04:32 AM

Improvement in contralateral motor scores during unilateral DBS at active contact locations in and near the STN. From Eisenstein et al 2013 (submitted).
Back To Top

Follow us: